Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
104 participants
INTERVENTIONAL
2023-02-01
2025-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
• Can treatment with ZAX.1400.P03 for 3 weeks improve clinical signs of skin in psoriasis patients? Participants will be divided into two groups of 52 people. One group will use ZAX.1400.P03 topically twice daily for 3 weeks and the other group will use placebo topically twice daily for 3 weeks.
Researchers will compare treatment and placebo groups to see if there is any improvement in the clinical signs of skin caused by psoriasis after treatment with ZAX.1400.P03 for 3 weeks.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Climatotherapy Versus Topical Combination of Corticosteroids and Salicylic Acid in Treatment of Psoriasis
NCT03156062
Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients
NCT01936337
A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis
NCT02618616
Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis
NCT03359577
Natural Gels for Treatment of Plaque Psoriasis
NCT02330237
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Topical ZAX.1400.P03
ZAX.1400.P03, applied topically twice daily for 3 weeks after enrolment
ZAX.1400.P03
ZAX.1400.P03, applied twice daily for 3 weeks after enrolment
Placebo
Placebo, applied topically twice daily for 3 weeks after enrolment
Placebo
Placebo, applied twice daily for 3 weeks after enrolment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ZAX.1400.P03
ZAX.1400.P03, applied twice daily for 3 weeks after enrolment
Placebo
Placebo, applied twice daily for 3 weeks after enrolment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age range between 18 and 60 years
* Both sexes (male and female)
* Having written informed consent to participate in the study
* Lack of allergy to food and health products
* Only local tissue involvement and no need to take oral medications
* Absence of underlying diseases and immune deficiency
* Absence of pregnancy and breastfeeding
* Absence of blisters and infection caused by the disease
Exclusion Criteria
* Incidence of drug product allergy
* Occurrence of symptoms of skin, digestive, liver or kidney diseases
* Patient\'s lack of consent to continue for any reason
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zarrin Avaye Kowsar Salamat (ZAX company) and HerbmedX
UNKNOWN
Herbmedx Co
INDUSTRY
Fasa University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Akbar Farjadfar
Principle-Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fasa university of medical sciences
Fasa, Fars, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IR.FUMS.REC.1400.125
Identifier Type: OTHER
Identifier Source: secondary_id
IRCT20210218050404N5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.